ConcertAI's TeraRecon has integrated clinical and generative artificial intelligence (AI), aiming to enhance clinical research and patient care solutions.
These new features include AI orchestration, model development, visualisation, and multi-modal data management for enhanced clinical research capabilities.
The platform integrates various data types, including clinical, radiological, and digital pathology, to support AI model development for clinical trials and research.
As part of this launch, TeraRecon is launching a multi-modal AI platform supporting AI model development in collaboration with Memorial Sloan Kettering Cancer Center(MSKCC), focusing on advancing Clinical AI in oncology.
The partnership aims to predict tumour mutations and treatment responses using advanced data analysis and AI methods, contributing to oncology research.
Additionally, TeraRecon is expanding alliances within the Eureka Clinical AI Partner Program with various organisations, showcasing a Pulmonology Suite featuring vendor-neutral AI algorithms for analysing Chest CT scans in pulmonology.
The suite complements previously released Neurology and Cardiology Suites.
ConcertAI CEO Jeff Elton said: “Over the past two years, we have focused on the importance of multi-modal data AI model development, validation, stability monitoring, and deployment for insights, as part of clinical trials, and ultimately, clinical care.
“Multi-modal data enable causal inferences and elimination of confounders for interpretations and predictions.
“Enabling this required rethinking the tools available to biomedical researchers while leveraging the power of Generative AI.
“As a ground-up new approach that allows multi-modal data management, AI model development validation, model management, and model release we can bring the power of deep and wide data at scale, our large research network, and the latest predictive AI and Gen AI together for the broadest research community use.
“Having MSKCC as a multi-year strategic collaborator is an additional assurance of meeting our commitments to patients, clinical providers, and biomedical innovators at pace and the highest possible standards of outcomes.”
